Sanara MedTech Inc. Announces Launch of Tissue Health Plus Wound Care Provider Pilot Program
Sanara MedTech (Nasdaq: SMTI) has launched a pilot program through its subsidiary Tissue Health Plus (THP) for value-based wound care services. The program partners with a wound care provider group operating across six states to deliver at-home chronic wound care.
The THP technology platform will serve as the provider group's Wound Care Operating System, featuring the Co-Pilot software for standardizing patient encounters and treatment interventions. The platform includes two-way EMR integration to streamline administrative processes. The company aims to launch another pilot program with a payer in the second half of 2025.
Sanara MedTech (Nasdaq: SMTI) ha avviato un programma pilota tramite la sua controllata Tissue Health Plus (THP) per servizi di cura delle ferite basati sul valore. Il programma collabora con un gruppo di fornitori di cure per ferite operante in sei stati per offrire assistenza domiciliare per ferite croniche.
La piattaforma tecnologica THP fungerà da Sistema Operativo per la Cura delle Ferite del gruppo di fornitori, includendo il software Co-Pilot per standardizzare gli incontri con i pazienti e gli interventi terapeutici. La piattaforma integra un sistema EMR bidirezionale per semplificare i processi amministrativi. L’azienda prevede di avviare un altro programma pilota con un ente pagatore nella seconda metà del 2025.
Sanara MedTech (Nasdaq: SMTI) ha lanzado un programa piloto a través de su subsidiaria Tissue Health Plus (THP) para servicios de cuidado de heridas basados en valor. El programa se asocia con un grupo de proveedores de cuidado de heridas que opera en seis estados para ofrecer atención domiciliaria para heridas crónicas.
La plataforma tecnológica THP funcionará como el Sistema Operativo de Cuidado de Heridas del grupo de proveedores, incorporando el software Co-Pilot para estandarizar los encuentros con pacientes e intervenciones de tratamiento. La plataforma incluye integración bidireccional con EMR para agilizar los procesos administrativos. La compañía planea lanzar otro programa piloto con un pagador en la segunda mitad de 2025.
Sanara MedTech (나스닥: SMTI)는 자회사 Tissue Health Plus (THP)를 통해 가치 기반 상처 치료 서비스를 위한 파일럿 프로그램을 시작했습니다. 이 프로그램은 6개 주에서 운영되는 상처 치료 제공자 그룹과 협력하여 가정 내 만성 상처 치료를 제공합니다.
THP 기술 플랫폼은 제공자 그룹의 상처 치료 운영 시스템 역할을 하며, 환자 방문 및 치료 개입을 표준화하는 Co-Pilot 소프트웨어를 포함합니다. 이 플랫폼은 행정 절차를 간소화하기 위해 양방향 EMR 통합 기능을 갖추고 있습니다. 회사는 2025년 하반기에 또 다른 지급자와의 파일럿 프로그램을 시작할 계획입니다.
Sanara MedTech (Nasdaq : SMTI) a lancé un programme pilote via sa filiale Tissue Health Plus (THP) pour des services de soins des plaies basés sur la valeur. Ce programme s'associe à un groupe de prestataires de soins des plaies opérant dans six États afin de fournir des soins à domicile pour les plaies chroniques.
La plateforme technologique THP servira de système d'exploitation des soins des plaies pour ce groupe de prestataires, intégrant le logiciel Co-Pilot pour standardiser les consultations et les interventions de traitement. La plateforme comprend une intégration bidirectionnelle avec le dossier médical électronique (EMR) pour simplifier les processus administratifs. L'entreprise prévoit de lancer un autre programme pilote avec un payeur dans la deuxième moitié de 2025.
Sanara MedTech (Nasdaq: SMTI) hat über seine Tochtergesellschaft Tissue Health Plus (THP) ein Pilotprogramm für wertorientierte Wundversorgung gestartet. Das Programm arbeitet mit einer Wundversorgungsgruppe zusammen, die in sechs Bundesstaaten tätig ist, um chronische Wundversorgung zu Hause anzubieten.
Die THP-Technologieplattform dient als Wundversorgungs-Betriebssystem der Anbietergruppe und beinhaltet die Co-Pilot-Software zur Standardisierung von Patientenkontakten und Behandlungsmaßnahmen. Die Plattform verfügt über eine bidirektionale EMR-Integration, um administrative Prozesse zu vereinfachen. Das Unternehmen plant, in der zweiten Hälfte des Jahres 2025 ein weiteres Pilotprogramm mit einem Kostenträger zu starten.
- Launch of first-of-its-kind value-based wound care pilot program across six states
- Implementation of THP technology platform with two-way EMR integration capabilities
- Planned expansion of pilot program to include additional practitioners and locations
- Strategic advancement towards payer partnerships with new pilot program planned for H2 2025
- Real-world validation of the technology platform still pending
- Financial investment partners still needed for THP strategy execution
Insights
Sanara's wound care pilot program marks strategic advancement in their value-based care technology platform, offering modest future growth potential.
Sanara MedTech's subsidiary Tissue Health Plus (THP) has launched a pilot program with a wound care provider group that delivers at-home care across six states. This represents the company's first real-world implementation of their technology platform, which they're positioning as a "Wound Care Operating System."
The technology has two key components worth noting: the Co-Pilot software that standardizes patient encounters and treatment interventions while ensuring reimbursement compliance, and a two-way EMR integration capability that streamlines administrative processes. These features address meaningful pain points in wound care delivery - treatment standardization and documentation burden.
This pilot serves primarily as a validation mechanism rather than a revenue driver. Management's stated goals center on gathering real-world evidence to optimize their platform before wider deployment. The company is simultaneously pursuing two critical next steps: launching a payer-focused pilot in the second half of 2025 and securing financial partners to fund broader THP implementation.
While this development shows execution against their stated THP strategy, investors should recognize this as an early-stage validation effort. The announcement contains no financial metrics or projections regarding potential revenue impact. The company's decision to highlight this relatively modest operational milestone suggests measured progress rather than transformative near-term growth in their technology division.
Pilot program designed to provide real-world evidence in the use of Tissue Health Plus’ technology platform
FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC (“THP”), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as value-based primary care companies.
“We are pleased to announce that, during the second quarter, THP launched a pilot program in partnership with a wound care provider group delivering at-home care for chronic wounds across six states,” said Sam Muppalla, President and CEO of THP. “Through this initiative, the THP technology platform will serve as the provider group’s Wound Care Operating System. The group’s practitioners are leveraging THP’s Co-Pilot software offering to standardize patient encounter planning and treatment interventions, while ensuring compliance with reimbursement requirements. Additionally, the practitioners are utilizing the platform’s two-way integration with the group’s electronic medical record to streamline post-encounter administrative processes.”
Mr. Muppalla continued: “With respect to our goals for the pilot program, we believe the real-world experience gained through these patient encounters will enable us to further validate and optimize our THP technology platform. The wound care provider group has commenced the first patient encounters as part of this pilot program, and we look forward to expanding its use within the group to include additional practitioners and locations.”
“The initiation of our wound care provider pilot program represents an important milestone in our THP strategy, and we look forward to leveraging the data and feedback obtained through the real-world use of our THP technology platform to support its successful implementation,” stated Ron Nixon, Sanara's Executive Chairman and CEO. “In addition to this initiative, we remain acutely focused on engaging with payers – with the goal of launching a THP pilot program with a payer during the second half of this year – as well as with potential financial partners to invest in the execution of our THP strategy.”
Mr. Nixon continued: “We are pleased with THP’s performance and progress, and we look forward to sharing a full company update on our earnings call, which we intend to hold on August 13, 2025.”
About Tissue Health Plus
Tissue Health Plus (THP) is a pioneering healthcare company with the goal of transforming the
About Sanara MedTech Inc.
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets. The Company markets, distributes and develops surgical, wound and skin products for use by physicians and clinicians in hospitals, clinics and all post-acute care. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, TEXAGEN® Amniotic Membrane Allograft, and BIASURGE® Advanced Surgical Solution to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS® Antimicrobial Skin and Wound Cleanser, BIAKŌS® Antimicrobial Wound Gel, and BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution. Sanara's pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. For more information, please visit SanaraMedTech.com.
Information about Forward-Looking Statements
The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the efficacy of THP’s technology platform and payer programs, the planned expansion of the THP integrated wound care program, the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, the regulatory approval process and expansion of the Company’s business into value-based skincare, wound care and other services. These items involve risks, contingencies and uncertainties such as uncertainties associated with the development and process for obtaining regulatory approval for new products, the Company’s ability to validate and optimize the THP technology platform, the Company’s ability to build out its executive team, the Company’s ability to identify and effectively utilize the net proceeds of the CRG Term Loan Agreement to support the Company’s growth initiatives, the extent of product demand, market and customer acceptance, including acceptance of the THP technology platform, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.
Investor Relations Contact:
Jack Powell or Mike Piccinino, CFA
ICR Healthcare
IR@sanaramedtech.com
FAQ
What is Sanara MedTech's (SMTI) new wound care pilot program?
How does Sanara MedTech's THP Co-Pilot software work?
When will Sanara MedTech (SMTI) announce their next earnings?
What are Sanara MedTech's expansion plans for the THP pilot program?
Who is leading Sanara MedTech's THP initiative?
